“…In addition 17-AAG delivered via DMSO or Cremophor EL has a short half-life, limited ability to reach target cells, induction of drug resistance, poor specificity, and high hepatotoxicity that restrict its clinical use (Shin & Kwon, 2017). In recent years, advances in nanomaterials-based drug delivery carriers have paved the way for overcoming these obstacles (Deldar, Zarghami, Pilehvar-Soltanahmadi, Dadashpour, & Zarghami, 2017;Montazeri et al, 2017). The main advantages of nanocarriers for anticancer drugs include improved therapeutic effect, extended half-life in the bloodstream, increased water solubility, improved stability, selective delivery to specific site, and decreased hepatotoxicity (Firouzi-Amandi et al, 2018;Jalilzadeh-Tabrizi et al, 2018;Nejati-Koshki, Mortazavi, Pilehvar-Soltanahmadi, Sheoran, & Zarghami, 2017;Zamani, Pilehvar-Soltanahmadi, Alizadeh, & Zarghami, 2018).…”